Stay updated on Vicriviroc and Pembrolizumab in MSS CRC Clinical Trial
Sign up to get notified when there's something new on the Vicriviroc and Pembrolizumab in MSS CRC Clinical Trial page.

Latest updates to the Vicriviroc and Pembrolizumab in MSS CRC Clinical Trial page
- Check5 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3. The update appears to concern site versioning rather than the study details.SummaryDifference0.0%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check34 days agoChange DetectedRevision: v3.4.2 has been added. The previous funding-status notice and Revision: v3.4.1 have been removed.SummaryDifference0.4%

- Check41 days agoChange DetectedAdded a government funding lapse notice. Updated the site to revision v3.4.1, replacing v3.4.0.SummaryDifference0.4%

- Check48 days agoChange DetectedGlossary visibility was added and footer metadata was updated to include 'Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0', with capitalization changes in related labels.SummaryDifference0.2%

- Check62 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4. This is a minor version update with no impact on study content or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check84 days agoChange DetectedAdded a dedicated Locations section with regional site listings (Arizona, California, Florida, Tennessee, Texas, Alberta, and Quebec) and replaced the previous location blocks. The HHS Vulnerability Disclosure link was removed in this update.SummaryDifference0.8%

Stay in the know with updates to Vicriviroc and Pembrolizumab in MSS CRC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Vicriviroc and Pembrolizumab in MSS CRC Clinical Trial page.